Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Jul;13(7):1245-53.
doi: 10.1111/jth.13000. Epub 2015 Jun 15.

Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study

J Shatzel  1 , P S Dulai  1 , D Harbin  2 , H Cheung  2 , T N Reid  2 , J Kim  2 , S L James  2 , H Khine  2 , S Batman  2 , J Whyman  1 , R C Dickson  1   2 , D L Ornstein  1   2   3
Affiliations
Comparative Study

Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study

J Shatzel et al. J Thromb Haemost. 2015 Jul.

Abstract

Background: Hospitalized patients with cirrhosis are at increased risk for venous thromboembolism (VTE). The benefits and risks of pharmacological thromboprohylaxis in these patients have not been well studied.

Objectives: To examine the safety and efficacy of pharmacological VTE prophylaxis in hospitalized cirrhotic patients.

Patients/methods: Retrospective cohort study of patients with cirrhosis hospitalized at an academic tertiary care referral center over a 5-year period.

Results: Six hundred hospital admissions accounting for 402 patients were included. VTE prophylaxis was administered during 296 (49%) admissions. Patients receiving VTE prophylaxis were older (59 years vs. 55 years, P < 0.001), had longer lengths of stay (9.6 days vs. 6.8 days, P = 0.002), and lower Model for End-Stage Liver Disease scores (13.2 vs. 16.1, P < 0.001). In-hospital bleeding events (8.1% vs. 5.5%, P = 0.258), gastrointestinal bleeding events (3.0% vs. 3.2% P = 0.52), new VTE events (2.37% vs. 1.65%, P = 0.537), and mortality (8.4% vs. 7.3%, P = 0.599) were similar in the two groups. VTE prophylaxis did not reduce the risk of VTE (odds ratio 0.94, 95% confidence interval 0.23-3.71), and patients receiving unfractionated heparin, but not low molecular weight heparin, were at increased risk for in-hospital bleeding events (odds ratio 2.38, 95% confidence interval 1.15-4.94 vs. 0.87, 0.37-2.05, respectively).

Conclusion: The rate of VTE in this cohort of hospitalized cirrhotic patients was low and was unaffected by pharmacological thromboprophylaxis. Unfractionated heparin was associated with an increased risk for in-hospital bleeding, suggesting that if thromboprophylaxis is indicated, low molecular weight heparin may be favored.

Keywords: cirrhosis; low molecular weight heparin; prophylaxis; unfractionated heparin; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Conflict of Interests

The authors state that they have no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Inclusion/exclusion schema. Nine hundred ninety-six hospital admissions were identified for potential inclusion in the study, and 600 admissions involving 402 unique patients qualified for entry. *The unique patient number includes 66 patients with multiple admissions who received VTE prophylaxis during some admissions but not during others. These patients are therefore included in both the prophylaxis and no-prophylaxis groups, accounting for 235 and 233 patients, respectively.
See this image and copyright information in PMC

References

    1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585–93. - PubMed
    1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism The Worcester DVT Study. Arch Intern Med 1991; 151: 933–8. - PubMed
    1. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of venous thromboembolism in nonsurgical patients: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th edition). Chest 2012; 141: e195S–226S. - PMC - PubMed
    1. Aggarwal A, Puri K, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhotic patients: systematic review. World J Gastro 2014; 20: 5737–45. - PMC - PubMed
    1. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008; 53: 3012–7. - PubMed

Publication types

MeSH terms

Substances